Hormonal prostate cancer therapies and cardiovascular disease: a systematic review

Vittore Cereda, Pina T Falbo, Gaia Manna, Alessandro Iannace, Antonello Menghi, Michela Corona, Diana Semenova, Leonardo Calò, Roberto Carnevale, Giacomo Frati, Gaetano Lanzetta

Research output: Contribution to journalReview articlepeer-review


Therapeutic intervention for prostate cancer mostly relies on eliminating circulating androgen or antagonizing its effect at the cellular level. As the use of endocrine therapies grows, an under-reported incidence of cardiovascular toxicities occurs in prostate cancer patients. In this review, we summarize data of clinical studies, investigating the cardiovascular and metabolic alterations associated with the use of old and new endocrine drugs (gonadotropin-releasing hormone [GnRH] agonists and antagonists, androgen receptor inhibitors, 17α-hydroxylase/c-17,20-lyase [CYP17] inhibitor) in prostate cancer. To date, studies looking for links between cardiovascular complications and hormone-mediated therapies in prostate cancer have reached conflicting results. Several confounding factors, such as age of patients and related cardiovascular liability, other comorbidities, and use of concomitant drugs, have to be carefully evaluated in future clinical trials. Further research is needed given the continuous advancements being made in prostate cancer treatment.

Original languageEnglish
Pages (from-to)119-134
JournalHeart Failure Reviews
Issue number1
Publication statusPublished - Jan 2022


Dive into the research topics of 'Hormonal prostate cancer therapies and cardiovascular disease: a systematic review'. Together they form a unique fingerprint.

Cite this